Single-arm meta-analysis of EGFR-TKI rechallenge or continue treatment
Not Applicable
- Conditions
- EGFR mutated non-small cell lung cancer patients
- Registration Number
- JPRN-UMIN000051189
- Lead Sponsor
- Department of Respiratory Minami Kyousai Hospital
- Brief Summary
The initial EGFR-TKI-induced ILD rate was 13.6% (95% confidence interval [CI]:6.4-20.9). Readministration rate of EGFR-TKI after onset of EGFR-TKI-induced ILD was 40.2% (95% CI: 26.7-53.7). The successful readministration rate of EGFR-TKIs after onset of EGFR-TKI-induced ILD was 81.9% (95% CI: 73.8-90.0). Successful rate of EGFR-TKI readministration in patients with Grade 2 or higher adverse events post initial EGFR-TKI therapy was 76.1% (95% CI: 55.6-96.6).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 690
Inclusion Criteria
Not provided
Exclusion Criteria
without rechallenge others
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method continue rate of EGFR-TKI
- Secondary Outcome Measures
Name Time Method